At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 18 enrolled

Drug / intervention

Rituximab +1 moredrug

Likely dose

Rituximab 250mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00453102

NCT00453102Phase 2Completed

Compare CT.gov

Phase II Study of Ibritumomab Tiuxetan (Zevalin®) in Patients With Previously Untreated Marginal Zone Lymphoma

University of Miami·interventional·Posted Mar 28, 2007·Updated Jan 1, 2016

In Brief

A Phase 2 clinical trial evaluating Rituximab and Ibritumomab Tiuxetan for Marginal Zone Lymphoma. Completed, enrolled 18 participants across 1 site.

Detailed Summary

Zevalin may be an effective therapy for newly diagnosed marginal zone lymphoma (MZL).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMarginal Zone Lymphoma

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartFeb 2006

First PostedMar 2007

Primary CompletionFeb 2015

TodayJul 2026

First PostedMar 28, 2007

Enrollment StartFeb 1, 2006

Primary CompletionFeb 1, 2015

TodayJul 2, 2026

Enrollment to primary: 9 yearsPosted 19.3 years ago

Interventions

Rituximabdrug

IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³

Ibritumomab Tiuxetandrug

IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9: 0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³